Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394195 | 1.00 | MEN1 (1.00) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL29369964 | 1.00 | MEN1 (1.00) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| Ammonia Solution, Strong SCHEMBL29580190 | 0.99 | MEN1 (0.98) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL794085 | 0.85 | MEN1 (0.73) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL1430608 | 0.85 | MEN1 (0.73) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL20693802 | 0.84 | MEN1 (0.72) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL838875 | 0.84 | MEN1 (0.72) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL30545232 | 0.84 | MEN1 (0.72) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL838874 | 0.84 | MEN1 (0.72) | MEN1ALOX15CYP2C19KMT2AHSD17B10 | |
| SCHEMBL9344811 | 0.81 | MEN1 (0.69) | MEN1ALOX15CYP2C19KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-30 | — | — | US | claimed |
| EP-2841067-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | The Regents of The University of California (US) | 2015-03-04 | — | — | EP | claimed |
| WO-2013163455-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-31 | — | — | WO | claimed |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-11 | — | — | US | disclosed |
| US-11213494-B2 | Compositions and methods for the treatment of pervasive development disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-10555916-B2 | NMDAR antagonist for the treatment of pervasive development disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-11 | — | — | US | disclosed |
| EP-3485882-A1 | COMPOSITIONS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | Case Western Reserve University (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-2948135-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2019-01-02 | — | — | EP | disclosed |
| US-20180008559-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-01-11 | — | — | US | disclosed |
| CN-106793970-A | Nanoparring agents for diagnosis and therapy and processing thereof | 罗得岛医院 | 2017-05-31 | — | — | CN | disclosed |
| WO-2016040780-A1 | AMINOMETHYL- AND METHYLOXY-LINKED TRICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN AGGREGATION | NEUROPORE THERAPIES, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-1871749-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| EP-1773788-A2 | QUINAZOLINE DERIVATIVES | NOVARTIS-PHARMA GMBH (AT) | 2007-04-18 | — | — | EP | disclosed |
| US-20060293282-A1 | Substituted aminoalkanephosphonic acids | NOVARTIS AG (CH) | 2006-12-28 | — | — | US | disclosed |
| WO-2006108591-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006010591-A2 | QUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005049039-A1 | COMBINATIONS COMPRISING AMPA RECEPTORS ANTAGONISTS FOR THE TREATMENT OF AFFECTIVE AND ATTENTION DEFICIT DISORDERS | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| EP-1501518-A2 | SUBSTITUTED AMINOALKANEPHOSPHONIC ACIDS FOR THE TREATMENT OF NEUROPATHIC PAIN, AFFECTIVE AND ATTENTION DISORDERS, SCHIZOPHRENIA, TINNITUS, MYOPIA AND OTHER OCULAR DISORDERS | Novartis AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003092701-A2 | SUBSTITUTED AMINOALKANEPHOSPHONIC ACIDS FOR THE TREATMENT OF NEUROPATHIC PAIN, AFFECTIVE AND ATTENTION DISORDERS, SCHIZOPHRENIA, TINNITUS, MYOPIA AND OTHER OCULAR DISORDERS | NOVARTIS AG (CH) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293282-A1 | Substituted aminoalkanephosphonic acids | AANAT, LPAR6, AADAT | MEN1 1548/4885ALOX15 1766/4885CYP2C19 3443/4885 |
| US-20070208018-A1 | Quinazoline Derivatives | CYP3A5, CYP3A7, CYP3A4 | MEN1 1459/4885ALOX15 4662/4885CYP2C19 12/4885 |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2D, GRIN2A, GRIN2C | MEN1 4460/4885ALOX15 1269/4885CYP2C19 1313/4885 |
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | GRIN2A, GRIN1, GRIN2B | MEN1 2707/4885ALOX15 4379/4885CYP2C19 4877/4885 |
| US-11213494-B2 | Compositions and methods for the treatment of pervasive development disorders | GRIN2A, GRIN2C, GRIN2D | MEN1 4451/4885ALOX15 2265/4885CYP2C19 3525/4885 |
| US-20180008559-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2A, GRIN2C, GRIN2D | MEN1 4451/4885ALOX15 2265/4885CYP2C19 3525/4885 |
| US-10555916-B2 | NMDAR antagonist for the treatment of pervasive development disorders | MECP2, GRIN2A, GRIN2B | MEN1 4709/4885ALOX15 4441/4885CYP2C19 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.